A Phase 1, Double-blinded, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of BSG005 Following Single and Multiple Ascending Doses in Healthy Subjects
Latest Information Update: 23 Nov 2022
At a glance
- Drugs BSG 005 (Primary)
- Indications Mycoses
- Focus Adverse reactions
- Sponsors Biosergen
- 17 Nov 2022 Planned End Date changed from 1 Jun 2022 to 1 May 2023.
- 17 Nov 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Mar 2023.
- 17 Nov 2022 Status changed from not yet recruiting to recruiting.